The rapid development of the pharmaceutical industry and molecular biology research, especially on the tumor-associated immune microenvironment, has resulted in a variety of treatment options for lung adenocarcinoma patients including small-molecule tyrosine kinase inhibitors (TKIs) that target the EGFR/ALK/ROS1 (EAR) gene (Pakkala and Ramalingam, 2018) and immune checkpoint inhibitors that block the PD1/PD-L1 and B7/CTLA4 pathways (Bansal et al., 2016). This evidence concerns the gene CD274 and lung adenocarcinoma.